Combined Trial Reviews To Become The Norm In UK From 2022
Having gained enough experience with the combined ethics and regulatory review of clinical trial applications, the UK will make this its only route for evaluating new drug trial applications starting next year.
You may also be interested in...
Ongoing efforts by the UK to deliver a single decision on the ethical and regulatory approval of new clinical trial applications have reached a major milestone ahead of the 2022 mandatory deadline.
The MHRA intends to drop around 300 roles as it faces a financial crunch after leaving the EU and other pressures.
The UK government has set aside over £64m ($89m) to support the first phase of activities to be undertaken in the coming months under a two-part initiative to strengthen clinical research delivery.